ES2927193T3 - Proceso para la preparación de 2-(5-metoxiisocroman-1-il)-4,5-dihidro-1H-imidazol y su sal hidrogenosulfato - Google Patents
Proceso para la preparación de 2-(5-metoxiisocroman-1-il)-4,5-dihidro-1H-imidazol y su sal hidrogenosulfato Download PDFInfo
- Publication number
- ES2927193T3 ES2927193T3 ES18822414T ES18822414T ES2927193T3 ES 2927193 T3 ES2927193 T3 ES 2927193T3 ES 18822414 T ES18822414 T ES 18822414T ES 18822414 T ES18822414 T ES 18822414T ES 2927193 T3 ES2927193 T3 ES 2927193T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- methoxyisochroman
- ethyl
- carboxylate
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- GHIKYGQWBRHEGU-UHFFFAOYSA-N 2-(5-methoxy-3,4-dihydro-1h-isochromen-1-yl)-4,5-dihydro-1h-imidazole Chemical compound O1CCC=2C(OC)=CC=CC=2C1C1=NCCN1 GHIKYGQWBRHEGU-UHFFFAOYSA-N 0.000 title claims abstract description 21
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 title claims description 22
- UWSFLQCGSJNHIO-UHFFFAOYSA-N O.COc1cccc2C(OCCc12)C(=O)NCCN Chemical compound O.COc1cccc2C(OCCc12)C(=O)NCCN UWSFLQCGSJNHIO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- HZWPSPYSMWTZTG-UHFFFAOYSA-N 2-(5-methoxy-3,4-dihydro-1h-isochromen-1-yl)-4,5-dihydro-1h-imidazole;sulfuric acid Chemical compound OS(O)(=O)=O.O1CCC=2C(OC)=CC=CC=2C1C1=NCCN1 HZWPSPYSMWTZTG-UHFFFAOYSA-N 0.000 claims abstract description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000011541 reaction mixture Substances 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 24
- FORFRERTIVEGHW-UHFFFAOYSA-N ethyl 2-acetyloxy-2-[2-(2-methoxyphenyl)ethoxy]acetate Chemical compound CCOC(=O)C(OC(C)=O)OCCC1=CC=CC=C1OC FORFRERTIVEGHW-UHFFFAOYSA-N 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- HGBXERZBMCGOJC-UHFFFAOYSA-N COC1=C2CCOC(C2=CC=C1)C(=O)OCC Chemical compound COC1=C2CCOC(C2=CC=C1)C(=O)OCC HGBXERZBMCGOJC-UHFFFAOYSA-N 0.000 claims description 21
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims description 16
- XLDRDNQLEMMNNH-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethanol Chemical compound COC1=CC=CC=C1CCO XLDRDNQLEMMNNH-UHFFFAOYSA-N 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 15
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 14
- UGMOOEZNAKFMDK-UHFFFAOYSA-N 5-methoxy-3,4-dihydro-1H-isochromene-1-carboxylic acid Chemical compound COC1=C2CCOC(C2=CC=C1)C(=O)O UGMOOEZNAKFMDK-UHFFFAOYSA-N 0.000 claims description 12
- KQTXHRMCVANOIG-UHFFFAOYSA-M sodium 5-methoxy-3,4-dihydro-1H-isochromene-1-carboxylate Chemical compound COC1=C2CCOC(C2=CC=C1)C(=O)[O-].[Na+] KQTXHRMCVANOIG-UHFFFAOYSA-M 0.000 claims description 12
- 230000003197 catalytic effect Effects 0.000 claims description 11
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 10
- -1 2-acetoxy-2- ethyl (2-methoxyphenethoxy)acetate Chemical compound 0.000 claims description 9
- DBPFRRFGLYGEJI-UHFFFAOYSA-N ethyl glyoxylate Chemical compound CCOC(=O)C=O DBPFRRFGLYGEJI-UHFFFAOYSA-N 0.000 claims description 9
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 8
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 8
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 7
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 5
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 150000003510 tertiary aliphatic amines Chemical class 0.000 claims description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 3
- 108050002822 Alpha 2A adrenoceptor Proteins 0.000 abstract description 2
- 102100022815 Alpha-2A adrenergic receptor Human genes 0.000 abstract description 2
- 208000019901 Anxiety disease Diseases 0.000 abstract description 2
- 239000000048 adrenergic agonist Substances 0.000 abstract description 2
- 239000000730 antalgic agent Substances 0.000 abstract description 2
- 230000036506 anxiety Effects 0.000 abstract description 2
- 239000000932 sedative agent Substances 0.000 abstract description 2
- 230000001624 sedative effect Effects 0.000 abstract description 2
- 230000008484 agonism Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 5
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- VILAPLCRUHASPL-UHFFFAOYSA-N 2-(5-bromo-3,4-dihydro-1h-isochromen-1-yl)-4,5-dihydro-1h-imidazole Chemical compound O1CCC=2C(Br)=CC=CC=2C1C1=NCCN1 VILAPLCRUHASPL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- CINYPUUJTPPQGX-UHFFFAOYSA-N methyl 5-bromo-3,4-dihydro-1h-isochromene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)OCCC2=C1Br CINYPUUJTPPQGX-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GOCCREQJUBABAL-UHFFFAOYSA-N 2,2-dihydroxyacetic acid Chemical compound OC(O)C(O)=O GOCCREQJUBABAL-UHFFFAOYSA-N 0.000 description 1
- ADLOWZRDUHSVRU-UHFFFAOYSA-N 2-(2-bromophenyl)ethanol Chemical compound OCCC1=CC=CC=C1Br ADLOWZRDUHSVRU-UHFFFAOYSA-N 0.000 description 1
- GPLALQLOOZVAGJ-UHFFFAOYSA-N 5-bromo-3,4-dihydro-1h-isochromene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)OCCC2=C1Br GPLALQLOOZVAGJ-UHFFFAOYSA-N 0.000 description 1
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 1
- DMDDBMBJQISVOL-UHFFFAOYSA-N C(C)C(=O)O.COC1=C2CCOCC2=CC=C1 Chemical compound C(C)C(=O)O.COC1=C2CCOCC2=CC=C1 DMDDBMBJQISVOL-UHFFFAOYSA-N 0.000 description 1
- 229910008433 SnCU Inorganic materials 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- HAMPDRBRDOCRSN-UHFFFAOYSA-N ethyl 2-hydroxy-2-[2-(2-methoxyphenyl)ethoxy]acetate Chemical compound CCOC(=O)C(O)OCCC1=CC=CC=C1OC HAMPDRBRDOCRSN-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Epoxy Resins (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20176085 | 2017-12-01 | ||
| PCT/FI2018/050864 WO2019106238A1 (en) | 2017-12-01 | 2018-11-30 | Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2927193T3 true ES2927193T3 (es) | 2022-11-03 |
Family
ID=64746580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18822414T Active ES2927193T3 (es) | 2017-12-01 | 2018-11-30 | Proceso para la preparación de 2-(5-metoxiisocroman-1-il)-4,5-dihidro-1H-imidazol y su sal hidrogenosulfato |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11352346B2 (enExample) |
| EP (1) | EP3717476B1 (enExample) |
| JP (1) | JP7339946B2 (enExample) |
| KR (1) | KR102718536B1 (enExample) |
| CN (1) | CN111630049B (enExample) |
| AU (1) | AU2018376872B2 (enExample) |
| BR (1) | BR112020010617A2 (enExample) |
| CA (1) | CA3083734A1 (enExample) |
| DK (1) | DK3717476T3 (enExample) |
| ES (1) | ES2927193T3 (enExample) |
| HR (1) | HRP20221247T1 (enExample) |
| HU (1) | HUE059849T2 (enExample) |
| IL (1) | IL274931B2 (enExample) |
| LT (1) | LT3717476T (enExample) |
| PL (1) | PL3717476T3 (enExample) |
| PT (1) | PT3717476T (enExample) |
| SI (1) | SI3717476T1 (enExample) |
| WO (1) | WO2019106238A1 (enExample) |
| ZA (1) | ZA202003981B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE112020003658T5 (de) | 2019-07-31 | 2022-05-19 | Hyundai Motor Company | Sdn-basiertes eindringungsverhinderungsverfahren für ein fahrzeuginternesnetz und system, das dieses verfahren verwendet |
| KR20230159515A (ko) * | 2021-03-19 | 2023-11-21 | 오리온 코포레이션 | 타시피미딘 제형 및 이의 용도 |
| JP2025502480A (ja) * | 2022-01-24 | 2025-01-24 | オリオン コーポレーション | イソクロマン－イミダゾール構造のアルファ－２ａアドレナリン受容体アゴニストの新規な硫酸塩形 |
| WO2023148431A1 (en) | 2022-02-04 | 2023-08-10 | Orion Corporation | Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist |
| JP2025531623A (ja) | 2022-09-28 | 2025-09-22 | オリオン コーポレーション | タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410562B1 (en) * | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| AR090557A1 (es) * | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
-
2018
- 2018-11-30 JP JP2020529522A patent/JP7339946B2/ja active Active
- 2018-11-30 KR KR1020207019100A patent/KR102718536B1/ko active Active
- 2018-11-30 PL PL18822414.1T patent/PL3717476T3/pl unknown
- 2018-11-30 HU HUE18822414A patent/HUE059849T2/hu unknown
- 2018-11-30 CN CN201880076883.0A patent/CN111630049B/zh active Active
- 2018-11-30 WO PCT/FI2018/050864 patent/WO2019106238A1/en not_active Ceased
- 2018-11-30 BR BR112020010617-8A patent/BR112020010617A2/pt unknown
- 2018-11-30 AU AU2018376872A patent/AU2018376872B2/en active Active
- 2018-11-30 SI SI201830738T patent/SI3717476T1/sl unknown
- 2018-11-30 HR HRP20221247TT patent/HRP20221247T1/hr unknown
- 2018-11-30 ES ES18822414T patent/ES2927193T3/es active Active
- 2018-11-30 PT PT188224141T patent/PT3717476T/pt unknown
- 2018-11-30 LT LTEPPCT/FI2018/050864T patent/LT3717476T/lt unknown
- 2018-11-30 DK DK18822414.1T patent/DK3717476T3/da active
- 2018-11-30 EP EP18822414.1A patent/EP3717476B1/en active Active
- 2018-11-30 US US16/768,093 patent/US11352346B2/en active Active
- 2018-11-30 CA CA3083734A patent/CA3083734A1/en active Pending
- 2018-11-30 IL IL274931A patent/IL274931B2/en unknown
-
2020
- 2020-06-30 ZA ZA2020/03981A patent/ZA202003981B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11352346B2 (en) | 2022-06-07 |
| HUE059849T2 (hu) | 2023-01-28 |
| US20200308152A1 (en) | 2020-10-01 |
| JP7339946B2 (ja) | 2023-09-06 |
| RU2020121597A3 (enExample) | 2022-01-04 |
| EP3717476B1 (en) | 2022-08-03 |
| LT3717476T (lt) | 2022-09-26 |
| AU2018376872B2 (en) | 2023-12-07 |
| CN111630049A (zh) | 2020-09-04 |
| IL274931A (en) | 2020-07-30 |
| HRP20221247T1 (hr) | 2022-12-09 |
| EP3717476A1 (en) | 2020-10-07 |
| BR112020010617A2 (pt) | 2020-11-10 |
| RU2020121597A (ru) | 2022-01-04 |
| KR102718536B1 (ko) | 2024-10-21 |
| PT3717476T (pt) | 2022-08-23 |
| SI3717476T1 (sl) | 2022-10-28 |
| IL274931B2 (en) | 2023-11-01 |
| WO2019106238A1 (en) | 2019-06-06 |
| JP2021504418A (ja) | 2021-02-15 |
| CA3083734A1 (en) | 2019-06-06 |
| AU2018376872A1 (en) | 2020-07-16 |
| PL3717476T3 (pl) | 2022-11-21 |
| IL274931B1 (en) | 2023-07-01 |
| KR20200095519A (ko) | 2020-08-10 |
| CN111630049B (zh) | 2023-06-20 |
| DK3717476T3 (da) | 2022-09-05 |
| ZA202003981B (en) | 2021-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3717476B1 (en) | Process for the preparation of 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1h-imidazole and the hydrogensulfate salt thereof | |
| EP3668857B1 (en) | Processes for the preparation of niraparib and intermediates thereof | |
| BR112015029714B1 (pt) | Processo para preparar derivados de 4,6-bis(ariloxi)pirimidina | |
| JP2005507900A (ja) | シタロプラムの製造方法 | |
| JP6149104B2 (ja) | トリアゾール化合物の調製方法 | |
| WO2018187717A1 (en) | Continuous flow synthesis of ibuprofen | |
| US10787420B2 (en) | Benzimidazole compound and preparation method thereof | |
| WO2014128139A1 (en) | Process for the preparation of enantiomerically enriched 3-aminopiperidine | |
| CN103183673B (zh) | (s,s)-2,8-二氮杂双环[4,3,0]壬烷的合成方法 | |
| EP3727377A1 (en) | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| US20100267954A1 (en) | Process for the purification of paliperidone | |
| US8080663B2 (en) | Process for the preparation of 2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine | |
| US11932614B2 (en) | Method for preparing diazoxide | |
| RU2791469C2 (ru) | Способ получения 2-(5-метоксиизохроман-1-ил)-4,5-дигидро-1h-имидазола и его гидросульфата | |
| WO2016071382A1 (en) | Synthesis of pi3k inhibitor and salts thereof | |
| WO2019167058A1 (en) | An improved process for the preparation of propiomazine maleate | |
| CN106632077A (zh) | 一种2‑氨基‑4‑溴嘧啶的制备方法 | |
| CN107778307B (zh) | 一种中枢性α2肾上腺素受体激动剂的制备方法 | |
| WO2023086696A2 (en) | Apparatus and methods for continuous flow synthesis of cisatracurium | |
| CN107098868B (zh) | 一种帕立骨化醇中间体的制备方法 | |
| BR112020011901B1 (pt) | Processo para preparar derivados anti-helminticos de 4-aminoquinolina-3-carboxamida | |
| HK1230509A1 (en) | Clomiphene synthesis using a single solvent | |
| IT201900009777A1 (it) | Processo per la sintesi di lofexidina |